News | June 07, 2022
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The company has posted net loss of Rs. 67.65 crores for the Financial Year ended March 31, 2022
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
AstraZeneca also played a critical role in the global response to COVID-19.
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
These and many other questions gather worldwide experts of the pharmaceutical industry at the PHARMAP 2022 which takes place in Berlin, Germany on June, 20 - 21, 2022
Subscribe To Our Newsletter & Stay Updated
